Molecular Imaging in NHP Models For Translational Drug Development

Molecular imaging is increasingly being used to generate quantitative and longitudinal evidence throughout preclinical drug development. When it is combined with well-characterized non-human primate (NHP) models, imaging can help researchers move beyond conventional endpoint measurements to investigate where a therapeutic goes, whether it reaches and engages its intended target, and how biological responses evolve over time.

The webinar will focus on the practical value of integrating molecular imaging with NHP disease models, PK/PD, biomarkers and other pharmacological endpoints to generate a fuller translational dataset.

The distinction that runs through the session is a simple one. Terminal tissue collection gives you one time point per animal; imaging gives you the whole curve from a single subject, and that changes what a distribution question can be asked about.

September 10, 2026 EDT 21:00 / PDT 18:00

What the Session Covers

In this webinar, Prisys Biotechnologies will discuss how PET, SPECT and MRI can be integrated with NHP research to support translational drug development. The speakers will introduce key imaging approaches and considerations, followed by selected case studies illustrating applications in CNS target engagement, biodistribution, therapeutic delivery and translational research.

The format suits teams that already run imaging as well as teams about to start. Each block moves from the technology to the decision it feeds: which tracer fits which question, what a quantitative readout looks like in practice, and where an imaging result still needs tissue or bioanalytical work before anyone can act on it.

>> Save Your Seat

What You Will Learn

How molecular imaging supports translational drug development
Key applications of PET, SPECT and MRI in NHP research
Approaches to assessing biodistribution and target engagement
How imaging can support longitudinal pharmacodynamic assessment
Integration of imaging with PK/PD and other translational endpoints
Practical NHP case studies in CNS research and therapeutic delivery

Key Topics

PET, SPECT and MRI: capabilities, applications and complementary roles
Radiotracer selection and considerations for quantitative molecular imaging
Target engagement and receptor occupancy, where appropriate
Longitudinal assessment of pharmacodynamic and biological responses
Molecular imaging applications in CNS research and NHP models
PET-based tracking of biologics, cells and other therapeutic modalities

Choices on Isotopes

Speakers

James Song, General Manager, PRISYS Biotech

As General Manager of Prisys Biotech, James Song brings 20 years of experience in NHP Pharmacology and disease modeling to the work of moving programs from lab to clinic. He specializes in the practical side of translational medicine, with a track record in managing high-value asset restructuring and building international alliances. Under his leadership, Prisys has extended its laboratory infrastructure, its NHP models and its integrated NHP breeding operations.

Message Presenter